To compare health-related quality of life (HRQOL) between patients with localised prostate cancer in an active surveillance (AS) group and a radical prostatectomy (RP) group, as evidence shows that both groups have similar oncological outcomes. Thus, comparative findings on the patients' HRQOL are becoming even more important to allow for informed treatment decision-making.
Introduction
Prostate cancer is often diagnosed in a localised state [1] , with a good prognosis when a low-risk profile is present [2] [3] [4] . According to current guidelines [5] recommended treatment options in a curative setting include radical prostatectomy (RP) and active surveillance (AS). For quite some time, RP has been the state-of-the-art treatment for localised prostate cancer. However, studies revealed that it leads to a significant decline in health-related quality of life (HRQOL), especially in urinary and sexual function [6] [7] [8] . AS is an alternative non-invasive approach for selected patients with growing acceptance. Patients are regularly monitored and only switched to an invasive treatment when signs of progression occur. Recent studies showed similar oncological outcomes for AS and RP in low-risk prostate cancer [9] [10] [11] . A negative impact on HRQOL has so far not been demonstrated [6, 12, 13] . The assumption that knowledge of having an untreated disease leads to higher levels of anxiety in AS patients has been disproven by several studies [12, 14, 15] .
Against this background, the HRQOL of patients under AS and RP becomes an even more important area of interest, as findings on group differences over time can help physicians and patients in their treatment decisions. HRQOL covers the 'subjective perceptions of the positive and negative aspects of cancer patients' symptoms, including physical, emotional, social, and cognitive functions and, importantly, disease symptoms and side effects of treatment' [16, p. 120] . Current research shows an inconsistent image regarding HRQOL, partly due to heterogeneous study designs and HRQOL instruments. To date, a wide variety of instruments are used [17] , making comparisons between studies difficult. Also, reliable data on HRQOL and prospective studies matching the different treatment options are rare. The few existing studies mainly showed differences in erectile and urinary function [6, 18, 19] , with patients under AS showing better functioning than with RP. However, Donovan et al. [7] could not find any difference in global HRQOL and functioning, although the prior mentioned physical impairments were obvious. The prospective randomised Prostate Cancer Intervention Versus Observation Trial (PIVOT) [20] compared RP with 'watchful waiting' (WW), although the treatment could rather be considered as a mixture of WW and adapted AS, which is demonstrated by the high rate of curatively intended therapies. The study revealed inconsistent results regarding HRQOL after a follow-up of 19 years. No differences were found for overall, physical and mental health, whereas functional outcomes, such as limitations of activities in daily living and sexual function, indicated substantial differences in favour of the WW patients. These functional aspects of prostate cancer treatment can have a great impact on patients' HRQOL, independent from the frequently reported direct symptoms of erectile and urinary dysfunction. However, they are seldom studied. In the present study, we aimed to focus on global and functional HRQOL measures (physical, role, emotional, cognitive, and social functioning) in patients with low-risk prostate cancer and offer an analysis of longitudinal data with a follow-up of 3.5 years. The objective was to test the hypothesis that the HRQOL of AS patients is as high as or exceeds the HRQOL of RP patients, after controlling for age, partnership status, and comorbidities.
Patients and Methods

Study Population
The data were collected within the Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting (HAROW) study, a prospective, multicentre, observational health services research study. It was designed to collect data of different treatment options for newly diagnosed patients with localised prostate cancer (T1-2, N0, M0) in Germany under real-world conditions. HAROW stands for the initials of five possible treatment options of localised prostate cancer: hormonal treatment (HT), AS, radiotherapy (RT), operation (RP) and WW. The HAROW study was approved by the Ethics Committee of the Bavarian State Board of Physicians. Details on the study have been published elsewhere [21, 22] .
From July 2008 to July 2013, 3 169 patients with a newly diagnosed clinically localised prostate cancer (≤cT2) were enrolled by 259 physicians, of which 86% were office-based urologists. In total, 1 764 patients (55.6%) underwent RP and 487 patients (15.4%) chose AS. Patients available for the analysis encompass 961 (30.3%) patients with low-risk cancer and available HRQOL data (Fig. 1) . Of those, 556 (57.9%) received RP and 405 (42.1%) AS. The baseline survey (time-0) was administered before RP, but after the diagnosis. The following assessments took place every 6 months. Due to consecutive enrolment and discontinuations over the study period of 5-years, only data from the first seven data collections (time-0 to time-7; 3.5 years) were considered. The mean follow-up time in this sample was 1.8 years (median 2 years).
Since AS was a rather new strategy at the beginning of the study, and not considered in the guidelines at that time, recommendations for an inclusion in AS were given as: ≤cT2c, PSA level of ≤10 ng/mL, Gleason score ≤6, PSA density ≤0.2 ng/mL, and ≤2 positive biopsies out of a 12-core biopsy. These recommendations reflected those, given in the literature [23, 24] and the European Prostate Cancer Research International Active Surveillance (PRIAS) study [25] , the largest published prospective study of AS at that time. The clinical follow-up of patients on AS should include DRE, PSA level and determination of PSA-doubling time (PSA-DT) every 3 months during the first 2 years and 6-monthly thereafter. A re-biopsy should be done after 1 year and then at 3-year intervals. The criteria for AS discontinuation, due to a suspected progression of the disease, included an increase in PSA levels with a PSA-DT of <3 years, Gleason score progression >6 on re-biopsy or clinical progression on DRE. Alternatively, upon patient's request. Data on clinical results of the AS cohort have been published elsewhere [22] . During follow-up, 112 patients switched to a deferred treatment: 65 chose RP, 30 RT, 10 HT, and seven WW. HRQOL data were evaluated until the time point in which AS was terminated.
Main Outcome Measure
Patients completed written postal questionnaires indicating general sociodemographic data and HRQOL every 6 months. Their physicians added information on diagnosis, comorbidity, and treatment. HRQOL was assessed by the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire 30-item core (EORTC QLQ-C30), an established and validated cancer-specific measure of HRQOL [26, 27] . The instrument has widely been used in various national and international studies. The questionnaire consists of 30 items that result in one global HRQOL score, five functional scores (physical, role, emotional, cognitive, and social functioning), and nine items for cancer-specific symptoms. The higher the average value of the functional scale, the higher the HRQOL in the examined dimension. For the present analysis, we focus on global health status and the functional scales as a first step in the analysis. Symptom scales will be the subject of future analyses. The instrument demonstrated good psychometric properties and clinical validity in earlier studies [27] .
Independent Variables and Covariates
The therapy regimes AS vs RP were treated as the binary independent variable. As an indicator for risk of progression D'Amico risk categories were defined, and all tumours with a PSA level ≤10 ng/mL, Gleason Score ≤6 and a clinical TCategory ≤T2a were considered as low risk [3] . Comorbidities were assessed with the Charlson Comorbidity Index (CCI), which considers the number and severity of comorbidities [28, 29] . Age and partnership status were assessed as sociodemographic characteristics.
Statistical Models
HRQOL scores were calculated according to the user manual for the EORTC QLQ-C30, resulting in scores ranging from 0 to 100, with higher scores representing a better HRQOL in the functional scales [27] . Firstly, descriptive statistics were calculated for the sociodemographic and illness-related characteristics, treatment, and HRQOL. Descriptives for the HRQOL scales have been adjusted by covariance analysis with the treatment group as a factor and age, partnership status, and CCI as covariates.
Secondly, we performed analyses with a focus on a comparison between AS and RP in terms of their effect on patient HRQOL. Longitudinal multilevel modelling was chosen in order to estimate and explain patient-specific trends in HRQOL over time. In multilevel models for longitudinal data, the lowest level of data is the specific measurement at a particular time (time-points). This lowest level is referred to as 'Level-1' data. Each Level-1 measurement is nested within a particular research participant (patient). The individual, then, constitutes 'Level-2' data. In this study, longitudinal two-level random intercept linear multilevel models for each of the five HRQOL functional scales and the global HRQOL scale as dependent variables were calculated, where time-points are Level-1-units and patients are Level-2-units ( Fig. 2) [30, 31] . The random intercept model models intercepts that vary across patients in order to detect differences in HRQOL by personal and treatment-related patient characteristics. In a first step, twolevel models with only time points included as dummy variables (null models) were fitted in order to calculate the intraclass correlation coefficient (ICC). The ICC provides an insight into the degree in which the outcome (HRQOL) varies between patients. In the second step, treatment (AS vs RP), sociodemographic, and illness-related characteristics were added to the models as dummy variables. Missing data were included as separate dummy variables to avoid case deletion. No imputations were performed. Descriptive analyses were performed with the Statistical Package for the Social Sciences (SPSS â ), version 22 (SPSS Inc., IBM Corp., Armonk, NY, USA) and HLM 7.0 (Scientific Software International, Inc., Skokie, IL, USA) was used for multilevel analyses.
Results
Descriptive Results
Descriptive data of the sample of 961 patients with low-risk prostate cancer, differentiated by treatment group is shown in Table 1 . The mean age was 63.9 years in the RP group and 67.7 years in the AS group (P < 0.001). There were no significant differences by treatment group for comorbidities When comparing AS and RP patients, global HRQOL, physical, emotional and role functioning are higher for AS than RP patients within 1 year after diagnosis (time-0 to time-2). After 1 year, the HRQOL of RP patients has increased and adjusts to the AS patients' level of HRQOL; some scores slightly and intermediately exceed the AS patients' scores. In role functioning, RP patients reach AS patients' scores only in the third year after diagnosis. However, social functioning for RP patients remains and stays clearly below that of AS patients over time. In cognitive functioning the treatment groups are congruent.
Longitudinal Multilevel Modelling In the multilevel model, all seven time points (up to 3.5 years) were included as predictors on Level 1 (time level) in order to take into account the nested structure of data (time points nested in patients). The results for Level 1 show whether the HRQOL at each time point significantly differs from baseline at time-0 and thus indicates the dynamic within the HRQOL measurement over time for all patients under study, irrespective of the treatment option. Whereas for global HRQOL, role, emotional and cognitive functioning the scores for almost all time points significantly differ from the baseline score, and this is not the case for physical and social functioning. Thus, the dynamic in HRQOL is stronger for global HRQOL, role, emotional, and cognitive; however, those differences again do not reach clinical meaningfulness.
Discussion
The present analysis revealed higher scores for global HRQOL as well as for role, emotional and social functioning in AS patients compared to RP patients; however, only statistically and not clinically significant. Up to 1 year after diagnosis, the differences decrease; in global HRQOL and emotional functioning RP patients reach about the same scores of HRQOL as AS patients. However, in role functioning it takes RP patients up to 2 years to recover and reach the AS group. In social functioning, the RP group does not substantially improve over time and a substantial gap between RP and AS patients' remains up to 3.5 years after diagnosis. Our present results mainly concur with the results of Vanagas et al. [13] and their cross-sectional study that also used the EORTC QLQ-C30. There, patients under AS reached statistically and clinically significantly better levels in role, social and emotional functioning than patients under RP or HT.
A recent publication from Jeldres et al. [8] compared longitudinal HRQOL in a comparable prospective cohort. RP patients reported statistically and clinically significantly lower levels for sexual and urinary function on the Expanded Prostate Cancer Index Composite. The authors also found that physical, role and social functioning were lower for RP patients up to 6 months after treatment decision measured by the 36-item short-form health survey (SF-36) instrument; however, as in our present study, only social functioning revealed a clinically relevant difference within the first months after diagnosis. After 1 year, there were no differences between AS and RP compared to our present study, where it took 2 years for RP patients to reach the AS patients' level of role functioning. Moreover, RP patients in our present study consistently reported lower scores on social functioning compared to AS patients over the whole study period.
The recently published PIVOT study [20] compared patients under RP and WW in a randomised prospective design, with a follow-up of 19 years. Because at the beginning of the enrolment in 1994 AS did not exist in its present form, but slowly evolved, the WW group consisted of a mixture of WW and AS patients. HRQOL, measured with the EuroQoL five Dimensions three Levels (EQ-5D-3L), did not vary between the two arms for overall, physical and mental health, but RP patients reported higher limitations in activities of daily living, confirming differences in role functioning revealed in our present data as well.
A recent publication from the Prostate Testing for Cancer and Treatment (ProtecT) study [7] , a prospective and randomised trial comparing RP, RT and AS with respect to HRQOL, also used the EORTC-QLQ-C30 and longitudinal multilevel modelling. The ProtecT study found that RP had a strong negative effect on sexual functioning and urinary continence. Although there was some recovery, the outcomes remained worse in the RP group compared to AS and RT. For the EORTC-QLQ-C30 no significant differences were found. In comparison to the ProtecT study, our present data revealed significantly better scores in the EORTC-QLQ-C30 under AS compared to RP, at least for global HRQOL and three functional scales. The main strength of the ProtecT study is the prospective and randomised design, and the combination of different patient-reported outcomes. However, EORTC-QLQ-C30 was only assessed once (5 years after randomisation) and could not be followed over the course of therapy. In comparison, the HAROW study offers HRQOL data over a time course and considers comorbidities by CCI as a confounder, which is in contrast to ProtecT. The fact that patients in HAROW were not randomised, but made a treatment decision in cooperation with their urologist might be considered as an explanation for the contrast in findings.
The result that RP patients report a statistically significantly worse global HRQOL, role, emotional and social functioning within the first year after diagnosis can best be explained by the side-effects and consequences of RP, which over time partly recover. Additionally, role functioning might be affected by RP due to the limited ability of patients after surgery to follow their daily tasks and activities, such as work, hobbies, and other free-time activities. Concerning the rather long recovery time for RP patients in our present results, it has to be considered that RP patients started with a statistically significantly lower role functioning compared to AS patients, after controlling for age and comorbidity. This might be explained by the RP patient's early anticipation of problems in role functioning after RP (e.g., they might have suspended work before surgery). The statistically significantly lower baseline measure in emotional functioning for RP might be due to the patients knowing that they will undergo surgery and thus are more psychologically stressed and anxious. On the other hand, higher levels of distress when facing a cancer diagnosis might lead to a more radical treatment decision [32] . The RP patients' clinically significantly lower baseline measure of social functioning, with a further decline up to 6 months after diagnosis might again be explained by patients' tendency towards a surgical treatment option, when social functioning is substantially impaired by the diagnosis. After surgical treatment, RP patients do not reach the stable level in social functioning of AS patients at any time point. Thus, RP patients might be less socially active at the time of diagnosis due to anticipation of surgery and it is a common phenomenon of severely ill patients to lose ties in their social network after diagnosis and treatment [33, 34] . The findings for the rather general outcome of global HRQOL are consistent with the results of role and emotional functioning. The finding that cognitive functioning was not affected by treatment group was an expected result, as none of the treatments should have an effect on cerebral function.
Our present study confirms a lower HRQOL in patients with a higher burden of comorbidities, which is also shown by a large number of epidemiological studies [35, 36] . The status of comorbidities should always be considered and critically discussed when weighing the different therapy options. Younger patients showed significantly lower values in social, emotional, role and cognitive aspects. This might be due to a different living situation with occupational and social commitments and could indicate that a cancer diagnosis at a younger age has a stronger impact on these particular dimensions of HRQOL.
Partnership status did not affect HRQOL in our present investigation. This clearly differs from previous studies, e.g., Segrin et al. [37] and Bellardita et al. [38] , which showed that HRQOL was significantly higher in married individuals. Moreover, patients without a partner were more likely to be diagnosed at a later stage, e.g., metastatic state of disease, were undertreated or even die earlier [39] . In our present setting, it may be the early and localised state of disease that reduces this effect.
Strengths and Limitations
HAROW was designed as a longitudinal prospective study with a large number of patients and corresponding urologists. The multicentre approach represents the 'real-life' situation of patients with localised prostate cancer in everyday care. Due to the non-experimental design, the treatment decisionmaking was the responsibility of only patients and their physicians. Nevertheless, 85% of all AS patients were classified as low-risk patients, demonstrating that the given recommendations for an inclusion in AS were mainly respected. The non-randomised design is of course a limitation, as in functional dimensions of HRQOL such as emotional or social function, the patients' personality and preferences may be a confounder (e.g., patients with a better emotional functioning might be more comfortable with the uncertainty of AS and might therefore choose AS over RP). However, since randomised studies in patients with prostate cancer are very rare (ProtecT study) and a German study approach (Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or 'Early Intermediate' Risk [PREFERE] study) recently was discontinued due to serious recruitment problems, prospective observational studies are still valuable. Moreover, the observed differences in HRQOL between AS and RP are small. Except social functioning up to 6 months after diagnosis, the differences do not reach thresholds for clinical meaningfulness such as a change of at least 10 units in either domain or item score [40, 41] or a difference that exceeds half of a standard deviation of the baseline values [42] .
The study physicians were urged to enrol their patients consecutively in the study. Nevertheless, participation in the study was an individual decision leading to suboptimal response rates. Patients who did not take part in the HAROW study were treated normally outside the protocol. The surgical approach of RP (open retropubic, laparoscopic, robot-assisted) was not specified in HAROW, although at that time an open RP was the standard procedure in Germany, and it is still today, despite an increasing number of robot-assisted RPs. However, evidence, e.g. from Yaxley et al. [43] , shows that functional outcomes after 3 months did not differ between a robot-assisted and an open RP approach. A recent review including two unique studies with 446 randomised patients could not find any differences in the men's quality of life between these three surgical approaches [44] .
The baseline measurement was conducted directly after the diagnosis has been communicated to the patient and before
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© 2018 The Authors BJU International © 2018 BJU International treatment started. However, it is possible that at baseline patients already had decided on the treatment option, which could potentially have affected HRQOL at baseline. Moreover, the rather long follow-up of 3.5 years is still short for the evaluation of a slowly growing entity. We used longitudinal multilevel analysis, as an especially useful method for complex hierarchical data, which can be recommended for similar studies [30, 45] .
In conclusion, the present results show that patients with low-risk prostate cancer managed with AS in contrast to RP have at least the same and partly a higher level of global HRQOL as well as role, emotional and social function for a period of 3.5 years in an observational design. In some, but not all HRQOL scales, RP patients start with a lower HRQOL and recover up to the level of AS patients within 1-2 years after diagnosis. These results should be considered when advising patients about the different treatment options for low-risk localised prostate cancer.
